5J1V

Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.52 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.199 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: Design, synthesis, inhibitory potency and X-ray co-crystal structure.

Esvan, Y.J.Zeinyeh, W.Boibessot, T.Nauton, L.Thery, V.Knapp, S.Chaikuad, A.Loaec, N.Meijer, L.Anizon, F.Giraud, F.Moreau, P.

(2016) Eur.J.Med.Chem. 118: 170-177

  • DOI: 10.1016/j.ejmech.2016.04.004
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic hetero ...

    The design and synthesis of new pyrido[3,4-g]quinazoline derivatives is described as well as their protein kinase inhibitory potencies toward five CMGC family members (CDK5, CK1, GSK3, CLK1 and DYRK1A). The interest for this original tricyclic heteroaromatic scaffold as modulators of CLK1/DYRK1A activity was validated by nanomolar potencies (compounds 12 and 13). CLK1 co-crystal structures with two inhibitors revealed the binding mode of these compounds within the ATP-binding pocket.


    Organizational Affiliation

    Université Clermont Auvergne, Université Blaise Pascal, Institut de Chimie de Clermont-Ferrand, BP 10448, F-63000 Clermont-Ferrand, France; CNRS, UMR 6296, ICCF, F-63178 Aubière, France.,Structural Genomics Consortium, University of Oxford, Old Road Campus Building, Roosevelt Drive, Oxford OX3 7DQ, UK; Department of Clinical Pharmacology, University of Oxford, Old Road Campus Building, Roosevelt Drive, Oxford OX3 7DQ, UK.,Université Clermont Auvergne, Université Blaise Pascal, Institut de Chimie de Clermont-Ferrand, BP 10448, F-63000 Clermont-Ferrand, France; CNRS, UMR 6296, ICCF, F-63178 Aubière, France. Electronic address: Pascale.MOREAU@univ-bpclermont.fr.,ManRos Therapeutics, Centre de Perharidy, 29680 Roscoff, France.,Université Clermont Auvergne, Université Blaise Pascal, Institut de Chimie de Clermont-Ferrand, BP 10448, F-63000 Clermont-Ferrand, France; CNRS, UMR 6296, ICCF, F-63178 Aubière, France. Electronic address: Francis.GIRAUD@univ-bpclermont.fr.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Dual specificity protein kinase CLK1
A, B, C
339Homo sapiensMutation(s): 0 
Gene Names: CLK1 (CLK)
EC: 2.7.12.1
Find proteins for P49759 (Homo sapiens)
Go to Gene View: CLK1
Go to UniProtKB:  P49759
Small Molecules
Ligands 2 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
GOL
Query on GOL

Download SDF File 
Download CCD File 
A, C
GLYCEROL
GLYCERIN; PROPANE-1,2,3-TRIOL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
 Ligand Interaction
6FD
Query on 6FD

Download SDF File 
Download CCD File 
A, B, C
pyrido[3,4-g]quinazoline-2,10-diamine
C11 H9 N5
PQAQQDCVZZTPPJ-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.52 Å
  • R-Value Free: 0.244 
  • R-Value Work: 0.199 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 56.471α = 90.00
b = 116.021β = 99.28
c = 90.108γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
iMOSFLMdata reduction
REFMACrefinement
SCALAdata scaling

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Revision History 

  • Version 1.0: 2016-05-04
    Type: Initial release
  • Version 1.1: 2016-05-11
    Type: Database references